159 related articles for article (PubMed ID: 36212403)
1. Impact of genetic polymorphisms of drug transporters
Madejczyk AM; Canzian F; Góra-Tybor J; Campa D; Sacha T; Link-Lenczowska D; Florek I; Prejzner W; Całbecka M; Rymko M; Dudziński M; Orzechowska MJ; Jamroziak K
Front Oncol; 2022; 12():952640. PubMed ID: 36212403
[TBL] [Abstract][Full Text] [Related]
2. OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.
Kim YK; Lee SS; Jeong SH; Ahn JS; Yang DH; Lee JJ; Shin MG; Kim HJ
Chonnam Med J; 2014 Dec; 50(3):102-11. PubMed ID: 25568846
[TBL] [Abstract][Full Text] [Related]
3. Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib.
Loscocco F; Visani G; Ruzzo A; Bagaloni I; Fuligni F; Galimberti S; Di Paolo A; Stagno F; Pregno P; Annunziata M; Gozzini A; Barulli S; Gabucci E; Magnani M; Isidori A
Front Oncol; 2021; 11():672287. PubMed ID: 34055641
[TBL] [Abstract][Full Text] [Related]
4. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk.
Campa D; Butterbach K; Slager SL; Skibola CF; de Sanjosé S; Benavente Y; Becker N; Foretova L; Maynadie M; Cocco P; Staines A; Kaaks R; Boffetta P; Brennan P; Conde L; Bracci PM; Caporaso NE; Strom SS; Camp NJ; Cerhan JR; ; Canzian F; Nieters A
Int J Cancer; 2012 Aug; 131(4):803-12. PubMed ID: 21918980
[TBL] [Abstract][Full Text] [Related]
6. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
Salimizand H; Amini S; Abdi M; Ghaderi B; Azadi NA
Tumour Biol; 2016 Jan; 37(1):791-8. PubMed ID: 26250462
[TBL] [Abstract][Full Text] [Related]
7. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Skoglund K; Boiso Moreno S; Jönsson JI; Vikingsson S; Carlsson B; Gréen H
Pharmacogenet Genomics; 2014 Jan; 24(1):52-61. PubMed ID: 24322003
[TBL] [Abstract][Full Text] [Related]
8. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
de Lima LT; Vivona D; Bueno CT; Hirata RD; Hirata MH; Luchessi AD; de Castro FA; de Lourdes F Chauffaille M; Zanichelli MA; Chiattone CS; Hungria VT; Guerra-Shinohara EM
Med Oncol; 2014 Mar; 31(3):851. PubMed ID: 24469953
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
[TBL] [Abstract][Full Text] [Related]
11. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
12. Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Rinaldetti S; Pfirrmann M; Manz K; Guilhot J; Dietz C; Panagiotidis P; Spiess B; Seifarth W; Fabarius A; Müller M; Pagoni M; Dimou M; Dengler J; Waller CF; Brümmendorf TH; Herbst R; Burchert A; Janβen C; Goebeler ME; Jost PJ; Hanzel S; Schafhausen P; Prange-Krex G; Illmer T; Janzen V; Klausmann M; Eckert R; Büschel G; Kiani A; Hofmann WK; Mahon FX; Saussele S
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):266-271. PubMed ID: 29510895
[TBL] [Abstract][Full Text] [Related]
13. Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier.
Lemmen J; Tozakidis IE; Galla HJ
Brain Res; 2013 Jan; 1491():1-13. PubMed ID: 23123212
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro.
Skoglund K; Moreno SB; Baytar M; Jönsson JI; Gréen H
Pharmgenomics Pers Med; 2013; 6():63-72. PubMed ID: 24019750
[TBL] [Abstract][Full Text] [Related]
15. Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
Veerman GDM; Boosman RJ; Jebbink M; Oomen-de Hoop E; van der Wekken AJ; Bahce I; Hendriks LEL; Croes S; Steendam CMJ; de Jonge E; Koolen SLW; Steeghs N; van Schaik RHN; Smit EF; Dingemans AC; Huitema ADR; Mathijssen RHJ
EClinicalMedicine; 2023 May; 59():101955. PubMed ID: 37125403
[TBL] [Abstract][Full Text] [Related]
16. Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis.
Alves R; Gonçalves AC; Jorge J; Marques G; Ribeiro AB; Tenreiro R; Coucelo M; Diamond J; Oliveiros B; Pereira A; Freitas-Tavares P; Almeida AM; Sarmento-Ribeiro AB
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077209
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma.
Sun F; Chen Z; Yao P; Weng B; Liu Z; Cheng L
Front Pharmacol; 2021; 12():641075. PubMed ID: 33762959
[No Abstract] [Full Text] [Related]
18. Constitutive androstane receptor upregulates Abcb1 and Abcg2 at the blood-brain barrier after CITCO activation.
Lemmen J; Tozakidis IE; Bele P; Galla HJ
Brain Res; 2013 Mar; 1501():68-80. PubMed ID: 23340159
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium.
Martino A; Sainz J; Manuel Reis R; Moreno V; Buda G; Lesueur F; Marques H; García-Sanz R; Ríos R; Stein A; Dumontet C; Gemignani F; Maria Rossi A; Landi S; Jurado M; Petrini M; Jamroziak K; Campa D; Canzian F
J Hum Genet; 2013 Mar; 58(3):155-9. PubMed ID: 23303387
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the ATP-binding cassette transporters ABCB1, ABCG2 and ABCC5 by nuclear receptors in porcine blood-brain barrier endothelial cells.
Ho YS; Torres-Vergara P; Penny J
Br J Pharmacol; 2023 Dec; 180(23):3092-3109. PubMed ID: 37476954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
